Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Useful Bacteria Need Protection

04.07.2005


New forms of drugs for dysbacteriosis and other gastrointestinal disturbances are being developed by the Novosibirsk researchers with support of the International Science and Technology Center (ISTC).



A lot of Russians suffer from malfunction of gastrointestinal tract. The frequent reason for that is dysbacteriosis – disturbances of normal intestinal flora. To fight dysbacteriosis, physicians prescribe eubiotic drugs to patients, which contain bacteria necessary for digestion, for example, bifidumbacterin, lactobacterin, colibacterin, bificol, etc. The drugs are good, but upon intake they are destroyed in the stomach, due to that their efficiency reduces. To increase efficiency of eubiotics, they should be protected in some way.

This problem is being solved by the researchers of the State Research Center for Virology and Biotechnology “Vector” (“Vector-BiAlgam” close corporation (Koltsovo, Novosibirsk Region)) with support of the International Science and Technology Center (ISTC). Bacteria making part of the drugs need protection, and there are two main methods to defend them. The bacteria are either placed into a capsule – this is a capsulated form of drug, or they are placed on a special carrier - sorbent – this is an immobilized form.


The Novosibirsk researchers are developing and testing immobilized eubiotics. In this medication, cells of useful bacteria are placed on porous microcarrier SUMS-1 – aluminium oxide powder, the size of microparticles varying from 40 to 100 mkm, the surface of microparticles being covered by carbon (which is used in medicine as enterosorbent). Adsorption occurs on the carrier owing to both physical and chemical mechanisms. Proteins of the cellular wall of bacteria form chelates with the SUMS-1 surface, where magnesium serves as a complexing agent (chelation). In this case, active groups of bacteria’s proteins and lipoproteids turn out to be protected from the stomach’s aggressive acid medium. In the meantime, unprotected bifido- and lactobacteria lose more than 90 percent of their activity in the stomach, the immobilized ones go lossless through the stomach.

Chelates are known for their stability being dependent on the medium. As the stomach has acid medium, bacteria remains in it bound with sorbent. When the drug gets into lower parts of thin bowels, the chelate disintegrates due to increased. This is what is needed, because it is particularly in the thin bowels and than in the thick bowels that bifido- and lactobacteria get released from the carrier and start working. The released sorbent surface takes away toxins and metabolic products. SUMS-1 is a very efficient enterosorbent: it does not sorb small molecules - acids, carbohydrates, trace elements and it does not sorb large mass proteins either – transport proteins and enzymes. That is why the water-salt balance is not broken and bowel’ enzymatic activity does not decrease. Along with that, SUMS-1 actively binds proteins of medium mass, where toxins and products of uncomplete metabolism belong to. They are brought out of the organism together with the sorbent.

The Novosibirsk researchers have created complex eubiotic based on the SUMS-1sorbent, which includes consortium of several species of the most active cultures of bifido- and lactobacteria. These bacteria suppress reproduction of pathogenic, saprogenous and gas-producing microflora, they participate in peptic processes and synthesis of vitamins, in metabolism of trace elements and biologically active substances. On top of that, bifido- and lactobacteria act as immunostimulants.

New drugs underwent investigation at all levels. Testing them on laboratory animals, the researchers have made sure that they are non-toxic, do not cause side effects and at the same time destroy harmful intestinal flora and increase vital capacity of the organism. While clinical trials of the complex immobilized eubiotic are being prepared, the Novosibirsk State Medical Academy (based on the clinic) has already carried out clinical trials of its analogue called “Ecoflor”, which belongs to the category of bioactive nutritional supplements. 70 patients who were taking “Ecoflor” within two weeks have improved digestion and general habitus, and the gut organisms have become normal. The complex eubiotic production is still limited to pilot batches, and its analogue “Ecoflor” is already produced as a bioactive nutritional supplement.

And finally, it should be pointed out where new eubiotic drugs will be applied. They will be used not only for dysbacteriosis but also for toxin poisoning, enteric infection, pancreatitis, gastritis, ulcer and other chronic ailments, allergy, radiolesion and even tuberculosis and oncology treatment.

Sergey Komarov | alfa
Further information:
http://www.informnauka.ru

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>